Home » Biologics Discovery » Solution for Novel Biologics Modalities » ADC Discovery Service

ADC Discovery Service

One stop solution from target to preclinical candidates (PCC)

High-throughput internalization assay screening with antibodies supernatant

Antibody drug conjugates (ADCs) are new classes of biological drugs formed by conjugation technology combining toxin with monoclonal antibody (mAb) through a linker, which combines the targeting ability of antibody to tumor cells and the potent killing ability of toxin to achieve the advantage complementary synergistic therapy, and in recent years have come into an outbreak. With 20 years of antibody drug discovery experience, GenScript ProBio provides a one-stop ADC discovery service to customers, accelerating their research speed from target to ADC preclinical candidate molecules and preempting the research track.

- High-throughput internalization assay screening with antibodies supernatant
- Conduct pharmacology study in advance to evaluate efficacy and safety
- 20+ discovery project experiences in ADC targets, including HER2, EGFR, and TROP2
- 60+ ADC naked antibody discovery project experience
- 100+ ADC bioassay project experience
- Diverse antibody discovery technical campaigns: Hybridoma, phage display, single B cell screening, fully human antibody discovery
- 190+ ready-to-use payload-linker conjugates
- 7 types of ADC bioassay methods:
  Live-cell imaging-based Internalization, Toxin-conjugated mAb based cytotoxicity assay, bystander effect study
- One-stop service: pharmacodynamics, pharmacokinetics, toxicology

By Jan. 2024

Considerations in ADC Discovery

Payload-linker

Choose suitable payload

Choose suitable linker

Choose suitable conjugation method
Functionality, safety and developability

In vitro bioassay

In vivo pharmacology

Developability

Naked Antibody

High specificity

Species cross-reactivity
Suitable affinity

Excellent physicochemical properties
High internalization efficiency

Low immunogenicity

One-stop ADC Discovery Solution

GenScript ProBio provides a one-stop ADC discovery solution from target to preclinical candidates (PCC) ordered by high-throughput screening of naked antibodies, identifying functional antibody leads in the early stage, and conducting pharmacology study before antibody optimization.

Naked Antibody Discovery
Diverse antibody discovery technical campaigns, multiple molecular types, high-throughput antibody screening strategy

Service Highlights

Diverse antibody discovery technical campaigns:

Hybridoma, phage display, single B cell screening, fully human antibody discovery etc.
Multiple technical routes in parallel to improve project success
Multiple molecular types:
Monoclonal antibody, bispecific monoclonal antibody, single domain antibody, antibody fragment
High-throughput antibody screening strategy:
GenScript ProBio conducts high-throughput internalization screening in the supernatant screening stage to identify antibody leads with desirable internalization capability in the early discovery stage.
One stop antibody optimization solution:
GenScript ProBio offers a comprehensive solution of ADC antibody optimization service based on functionality and developability, which includes antibody humanization, antibody affinity tuning, Fc engineering(ADCC,CDC, ADCP enhancement, Fc silence, half-life extension).

Payload-linker Library and ADC Conjugation
150+ cytotoxins, 950+ linkers, 190+ ready-to-use payload-linker combos

Types of toxins available from Genscript ProBio (partial):

Payload categories	Products
Maytansinoid	DM1, DM2, DM3, DM4
Auristatins	MMAE, MMAD,MMAF
Eribulin derivatives	Eribulin Mesylate
Tubulysins	Tubulysin D, Tubulysin M
PBD Dimer	SG3199
Doxorubicin	PNU-159682
Camptothecin	Exatecan Mesylate
Amanitin derivatives	α-Amanitin
TLRs derivatives	Resiquimod
STING derivatives	Cyclic-di-GMP

Genscript ProBio offers a variety of ADC coupling modalities (Cysteine/Lysine based conjugation & site-specific conjugation) and evaluates conjugation quality based on the detection of DAR and ADC purity using a variety of methods including SDS-PAGE, HIC-HPLC, SEC-MS, RPLC-MS.

In Vitro Bioassay for ADC
Advanced ADC bioassay solution: Live-cell imaging based Internalization, Toxin-conjugated mAb based cytotoxicity assay, Bystander Effect

GenScript ProBio provides 7 different ADC bioassay methods for antibody internalization, cell cytotoxicity assays and bystander effect to meet the specific needs in ADC validation for our clients.

Scope	Internalization assay				Cytotoxicity assay	Bystander effect
Cell based assay	Live-cell imaging based Internalization	Toxin-conjugated mAb based cytotoxicity assay		pH-Indicator based Internalization	Temperature shift based Internalization	Cell growth inhibition assay	Medium transfer assay
General designation	IncuCyte	DT3C	FabFc-ZAP	pHrodo	Temperature Shift	Cytotoxicity assay	Bystander effect
Molecule	Naked Antibody					ADC or Toxin	ADC
Analyzer	Live-Cell Analyzer	Microplate Reader		FACS	FACS	Microplate Reader/ Live-Cell Analyzer	Microplate Reader
Feature	Real-time and kinetics analysis	High sensitivity High throughput Close to the cytotoxic MOA		Specific	Cost-effective Susceptible to multiple factors	High throughput	Simultaneous detection: Ag+ cell cytotoxicity and Ag- bystander effect
Application	Most versatile Best choice	Full range Cost-effective Alternative choice	High material cost	Client favor	For clients with limited budget	Full range	Bystander effect Potential security

80+ positive reference antibody dose-response curve (freely available)
Target cells 200+ tumor cell lines and 100+ overexpression cell lines

In Vivo Pharmacology for ADC
One-stop ADC in vivo pharmacology solution throughout the whole discovery process from drug design, screening to PCC confirmation

Genscript ProBio provides one-stop ADC in vivo pharmacology solution services including in vivo pharmacodynamic evaluation based on animals models, in vivo pharmacokinetics, preclinical toxicology studies, and biomarker assay, which are meet the compliance requirements for ADC declarations and assist you in faster, superior, and more provincial ADC development.

Extensive model resource
- Abundance of mouse strains
- 6 tumor bearing animal models
- 80+ Tumor cell models
- 200+ Tumor cell banks
- 24 Tumor indications
Pharmacokinetic experiments
- Method development and validation
- Pharmacokinetic experiments in cynomolgus monkeys and other primates
- Tissue distribution experiment
- Receptor mass experiments
Toxicological studies
- Toxicity with a single administration
- Dose exploration experiments
- Long-term toxicity testing
- Local toxicity
- Tissue cross-reactivity experiments

ADC Discovery Service

Balance functionality and safety

Excellent track record

One-stop ADC discovery solution

Considerations in ADC Discovery

One-stop ADC Discovery Solution

Service Highlights